KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.

Ambarish Pandey, Dalane W Kitzman, Khaja M Chinnakondepalli, Shachi Patel, Barry A Borlaug, Javed Butler, Melanie J Davies, Sanjiv J Shah, Subodh Verma, Cecilia Rönnbäck, Anne Domdey, Karoline Liisberg, Morten Schou, Eduardo Perna, Fozia Z Ahmed, Michael Fu, Mark C Petrie, Mikhail N Kosiborod

JACC Heart Fail 13(10) 102610

PMID40956259
PMCID-
DOI10.1016/j.jchf.2025.102610
发表日期2025-09-16
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Frailty is common in heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program, semaglutide improved heart failure (HF) symptoms and physical limitations and reduced body weight (BW) in participants with obesity-related HFpEF. Whether the efficacy and safety of semaglutide vary by frailty and the effects of semaglutide on frailty are unknown. OBJECTIVES: This study sought to evaluate the efficacy of semaglutide in participants with obesity-related HFpEF according to frailty status at baseline. METHODS: The authors performed a prespecified, pooled, participant-level analysis of the STEP-HFpEF program that included participants with obesity-related HFpEF. Participants were randomized to once-weekly semaglutide, 2.4 mg, or placebo for 52 weeks. Dual primary endpoints were changes in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and BW. Frailty was estimated using a cumulative deficit-derived frailty index comprising 34 variables across multiple domains at baseline and follow-up. Efficacy and safety of semaglutide were evaluated in participants across 3 baseline frailty strata. Effects of semaglutide on frailty burden were also assessed. RESULTS: Of the 1,145 participants, 110 (9.6%) were nonfrail, 343 (30.0%) were more frail, and 692 (60.4%) were most frail. Semaglutide-mediated weight loss was similar across frailty strata (Pinteraction = 0.38). However, the effects of semaglutide on KCCQ-CSS varied by frailty status; participants who were most frail had the greatest improvement at 52 weeks (nonfrail mean difference: -1.5 [95% CI: -8.4 to 5.4]; more frail mean difference: 3.7 [95% CI: -0.2 to 7.6]; most frail mean difference: 11.0 [95% CI: 8.1-13.8]; Pinteraction < 0.001). Semaglutide reduced the burden of frailty during follow-up (OR for being nonfrail at 52 weeks: 3.16 [95% CI: 2.44-4.09]; P < 0.0001). CONCLUSIONS: Semaglutide resulted in a similar reduction in BW across frailty subgroups but greater improvements in HF-related symptoms. Moreover, semaglutide reduced frailty burden after 52 weeks of treatment. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511) (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM]; NCT04916470).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。